AAPharmaSyn is a recognized leader in the development of custom proprietary lipids. Over the years we generated thousands of unique lipids with a wide range of biological activity and applications. Our proprietary methodology allows synthesis of lipids previously considered time and effort prohibitive. We specialize in the synthesis of:
Tuning lipids to enhance selective organ targeting (SORT)
The mechanistic study revealed that when selective organ targeting (SORT) molecules, a specific biophysical class, are incorporated into lipid nanoparticles (LNPs), they induce the formation of a distinct protein corona. This protein corona is essentially a layer of proteins that adsorb onto the surface of the nanoparticles once they are introduced into the biological environment. The composition and characteristics of this corona are crucial as they influence how the immune system and other cellular mechanisms recognize and process the nanoparticles. This recognition, in turn, determines the biodistribution and the ultimate site of mRNA delivery within the body.
Upon systemic administration, nanoparticles naturally tend to accumulate in the liver due to the organ's role in filtering and processing substances from the bloodstream. This liver tropism has been a significant challenge in the field, particularly for therapies where delivery to other organs is desired. Traditional LNPs often fail to efficiently target organs beyond the liver, limiting their therapeutic potential for a broader range of diseases and conditions.
The introduction of SORT molecules into LNPs has been a breakthrough in addressing this challenge. These molecules can modulate the surface properties of the LNPs, altering their interaction with the biological milieu and thereby influencing the formation of the protein corona. This modification enables more precise control over the nanoparticles' destination within the body. By adjusting the composition and characteristics of the SORT molecules within the LNPs, researchers can selectively target organs other than the liver, such as the spleen, lungs, and potentially other tissues.
This targeted delivery approach opens up new possibilities for treating diseases that affect specific organs and could significantly enhance the efficacy and safety of mRNA-based therapies. By fine-tuning the nanoparticle composition, researchers can design LNPs that bypass the liver and instead deliver their therapeutic cargo to the intended site, reducing off-target effects and increasing the therapeutic concentration at the desired location. This advancement represents a crucial step forward in the development of precision medicine and the optimization of mRNA delivery systems.
Possible modification include:
AAPharmaSyn has copious demonstrated experience to both design and execute synthesis of a complex lipid or a library of lipids. For more information, please contact us.
